Progress toward full adoption of CSTDs for drug preparation across facilities of all sizes continued even through the pandemic. Notable developments in this marketplace include the introduction of BD’s PhaSeal Optima and Fresenius Kabi’s purchase of Corvida’s Halo. Pharmacy’s additional purchasing plans mean this market will remain robust over the near term.
For more information, visit pppmag.com/automation and select Compounding, then CSTDs.
While the majority of CSTD users are committed to their current vendor, it is notable that more than 4 out of 10 users would consider switching to a new vendor.